Cargando…

The benefits, costs and feasibility of a low incidence COVID-19 strategy

In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have range...

Descripción completa

Detalles Bibliográficos
Autores principales: Czypionka, Thomas, Iftekhar, Emil N., Prainsack, Barbara, Priesemann, Viola, Bauer, Simon, Calero Valdez, André, Cuschieri, Sarah, Glaab, Enrico, Grill, Eva, Krutzinna, Jenny, Lionis, Christos, Machado, Helena, Martins, Carlos, Pavlakis, George N., Perc, Matjaž, Petelos, Elena, Pickersgill, Martyn, Skupin, Alexander, Schernhammer, Eva, Szczurek, Ewa, Tsiodras, Sotirios, Willeit, Peter, Wilmes, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720492/
https://www.ncbi.nlm.nih.gov/pubmed/35005678
http://dx.doi.org/10.1016/j.lanepe.2021.100294
_version_ 1784625140004290560
author Czypionka, Thomas
Iftekhar, Emil N.
Prainsack, Barbara
Priesemann, Viola
Bauer, Simon
Calero Valdez, André
Cuschieri, Sarah
Glaab, Enrico
Grill, Eva
Krutzinna, Jenny
Lionis, Christos
Machado, Helena
Martins, Carlos
Pavlakis, George N.
Perc, Matjaž
Petelos, Elena
Pickersgill, Martyn
Skupin, Alexander
Schernhammer, Eva
Szczurek, Ewa
Tsiodras, Sotirios
Willeit, Peter
Wilmes, Paul
author_facet Czypionka, Thomas
Iftekhar, Emil N.
Prainsack, Barbara
Priesemann, Viola
Bauer, Simon
Calero Valdez, André
Cuschieri, Sarah
Glaab, Enrico
Grill, Eva
Krutzinna, Jenny
Lionis, Christos
Machado, Helena
Martins, Carlos
Pavlakis, George N.
Perc, Matjaž
Petelos, Elena
Pickersgill, Martyn
Skupin, Alexander
Schernhammer, Eva
Szczurek, Ewa
Tsiodras, Sotirios
Willeit, Peter
Wilmes, Paul
author_sort Czypionka, Thomas
collection PubMed
description In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust.
format Online
Article
Text
id pubmed-8720492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87204922022-01-03 The benefits, costs and feasibility of a low incidence COVID-19 strategy Czypionka, Thomas Iftekhar, Emil N. Prainsack, Barbara Priesemann, Viola Bauer, Simon Calero Valdez, André Cuschieri, Sarah Glaab, Enrico Grill, Eva Krutzinna, Jenny Lionis, Christos Machado, Helena Martins, Carlos Pavlakis, George N. Perc, Matjaž Petelos, Elena Pickersgill, Martyn Skupin, Alexander Schernhammer, Eva Szczurek, Ewa Tsiodras, Sotirios Willeit, Peter Wilmes, Paul Lancet Reg Health Eur Health Policy In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust. Elsevier 2022-01-02 /pmc/articles/PMC8720492/ /pubmed/35005678 http://dx.doi.org/10.1016/j.lanepe.2021.100294 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Health Policy
Czypionka, Thomas
Iftekhar, Emil N.
Prainsack, Barbara
Priesemann, Viola
Bauer, Simon
Calero Valdez, André
Cuschieri, Sarah
Glaab, Enrico
Grill, Eva
Krutzinna, Jenny
Lionis, Christos
Machado, Helena
Martins, Carlos
Pavlakis, George N.
Perc, Matjaž
Petelos, Elena
Pickersgill, Martyn
Skupin, Alexander
Schernhammer, Eva
Szczurek, Ewa
Tsiodras, Sotirios
Willeit, Peter
Wilmes, Paul
The benefits, costs and feasibility of a low incidence COVID-19 strategy
title The benefits, costs and feasibility of a low incidence COVID-19 strategy
title_full The benefits, costs and feasibility of a low incidence COVID-19 strategy
title_fullStr The benefits, costs and feasibility of a low incidence COVID-19 strategy
title_full_unstemmed The benefits, costs and feasibility of a low incidence COVID-19 strategy
title_short The benefits, costs and feasibility of a low incidence COVID-19 strategy
title_sort benefits, costs and feasibility of a low incidence covid-19 strategy
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720492/
https://www.ncbi.nlm.nih.gov/pubmed/35005678
http://dx.doi.org/10.1016/j.lanepe.2021.100294
work_keys_str_mv AT czypionkathomas thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT iftekharemiln thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT prainsackbarbara thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT priesemannviola thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT bauersimon thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT calerovaldezandre thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT cuschierisarah thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT glaabenrico thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT grilleva thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT krutzinnajenny thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT lionischristos thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT machadohelena thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT martinscarlos thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT pavlakisgeorgen thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT percmatjaz thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT peteloselena thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT pickersgillmartyn thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT skupinalexander thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT schernhammereva thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT szczurekewa thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT tsiodrassotirios thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT willeitpeter thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT wilmespaul thebenefitscostsandfeasibilityofalowincidencecovid19strategy
AT czypionkathomas benefitscostsandfeasibilityofalowincidencecovid19strategy
AT iftekharemiln benefitscostsandfeasibilityofalowincidencecovid19strategy
AT prainsackbarbara benefitscostsandfeasibilityofalowincidencecovid19strategy
AT priesemannviola benefitscostsandfeasibilityofalowincidencecovid19strategy
AT bauersimon benefitscostsandfeasibilityofalowincidencecovid19strategy
AT calerovaldezandre benefitscostsandfeasibilityofalowincidencecovid19strategy
AT cuschierisarah benefitscostsandfeasibilityofalowincidencecovid19strategy
AT glaabenrico benefitscostsandfeasibilityofalowincidencecovid19strategy
AT grilleva benefitscostsandfeasibilityofalowincidencecovid19strategy
AT krutzinnajenny benefitscostsandfeasibilityofalowincidencecovid19strategy
AT lionischristos benefitscostsandfeasibilityofalowincidencecovid19strategy
AT machadohelena benefitscostsandfeasibilityofalowincidencecovid19strategy
AT martinscarlos benefitscostsandfeasibilityofalowincidencecovid19strategy
AT pavlakisgeorgen benefitscostsandfeasibilityofalowincidencecovid19strategy
AT percmatjaz benefitscostsandfeasibilityofalowincidencecovid19strategy
AT peteloselena benefitscostsandfeasibilityofalowincidencecovid19strategy
AT pickersgillmartyn benefitscostsandfeasibilityofalowincidencecovid19strategy
AT skupinalexander benefitscostsandfeasibilityofalowincidencecovid19strategy
AT schernhammereva benefitscostsandfeasibilityofalowincidencecovid19strategy
AT szczurekewa benefitscostsandfeasibilityofalowincidencecovid19strategy
AT tsiodrassotirios benefitscostsandfeasibilityofalowincidencecovid19strategy
AT willeitpeter benefitscostsandfeasibilityofalowincidencecovid19strategy
AT wilmespaul benefitscostsandfeasibilityofalowincidencecovid19strategy